Mengna Zhu
Union Hospital
Wuhan, 430022, China
Wuhan, 430022, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Correction: Combined CHK1 and PD-L1 blockade as a novel therapeutic strategy against stemness and immunosuppression in ovarian cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: February 12, 2026
Mapping CSC-Mediated Ovarian Cancer Chemoresistance via CXCR4-PET to Guide Precision Cisplatin Re-Sensitization Therapy.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: October 28, 2025
CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer.
Journal: Cell death & disease
Published: August 19, 2025
Combined CHK1 and PD-L1 blockade as a novel therapeutic strategy against stemness and immunosuppression in ovarian cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: July 12, 2025
The cyclin-dependent kinase inhibitor p27 facilitates chemosensitivity by promoting ferroptosis in epithelial ovarian cancer.
Journal: The Journal of biological chemistry
Published: April 22, 2025
Ivosidenib enhances cisplatin sensitivity in ovarian cancer by reducing cancer cell stemness.
Journal: Cancer drug resistance (Alhambra, Calif.)
Published: March 11, 2025
p27Kip1 and cytoplasmic pSer10p27 are promising biomarkers for predicting prognosis and chemotherapy response in ovarian cancer.
Journal: Histology and histopathology
Published: May 31, 2024
Loss of CBX2 causes genomic instability and Wnt activation in high grade serous ovarian carcinoma cells.
Journal: Molecular carcinogenesis
Published: September 01, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026